Slide Shows

As of this writing, the FDA has approved four novel drugs in the month of July, bringing the total number of approvals so far this year to 31.

The ten most valuable companies in the U.S., based on market capitalization, are worth over $11 trillion in total.

In June, as of this writing, two novel drugs have secured the FDA nod – Brexafemme and Aduhelm.

So far this month, only 2 *novel drugs have secured regulatory approval in the U.S. - Johnson & Johnson’s Rybrevant and Apellis Pharmaceuticals’ Empaveli - compared to 6 during the same period last year.